HBV

HBV/HDV-IN-3 (Compd 1) acts as a dual inhibitor for HBV and HDV, demonstrating an efficacy (EC 50) below 50 nM against HBV .

CCC-0975 is an inhibitor of hepatitis B virus (HBV) with an EC50 of 10 μM. It interferes with the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA) and reduces cccDNA and its precursor deproteinized rcDNA (DP-rcDNA), without promoting their degradation inside cells. CCC-0975 holds potential for chronic hepatitis B research.

TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.

HBV-IN-12: strong HBsAg & HBV DNA inhibitor; EC50 0.001-0.05 μM & 0.001-0.02 μM respectively. (WO2021204252A1)

HBV/HDV-IN-2 (Compd 143) functions as an inhibitor for HBV, HDV, and PD-1/PD-L1, demonstrating an EC 50 of 35 nM in T cell activation.

TLR8 agonist 4 inhibits wild-type and lamivudine/entecavir-resistant HBV; IC50: 0.15 μM and 0.10 μM.

HBV-IN-24 inhibits HBV DNA, HBsAg, HBeAg (EC50: 0.6, 0.6, 4.6 nM), and has antiviral properties with neurotoxicity mitigation.

SAG-524 is a powerful oral small molecule that inhibits HBV viral replication. In HepG2.2.15 cells, SAG-524 reduced HBV-DNA and HbsAg levels in the supernatant with IC₅₀ values of 0.92 nM and 1.4 nM, respectively [1].

FNC-TP trisodium, active intracellular FNC form, inhibits NRTI, fights HIV, HBV, and HCV.

HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) (EC50: 2790 nM).

ALG-000184, a prodrug of the potent HBV capsid assembly modulator ALG-001075, shows potential for use in HBV infection research.